Downloading...
Download

VRTX

VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH (1/9) Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀 (2/9) – REVENUE RUSH • Q4 Haul: $ 2.91B—16% jump from last year 💥 • Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊 • ‘25 Outlook: $11.75-$ 12B—6-9% growth NYSE:CF keeps humming—newbies add zest! (3/9) – BIG WINS • Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍 • Alyftrek: CF drug for 6+—ships now 🚗 • Cash: $11.2B—loaded for action 🌟 NASDAQ:VRTX storms pain—CF stays golden! (4/9) – SECTOR CHECK • Valuation: 11x sales—above 9x avg 📈 • Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium? • Growth: 12% beats biotech’s 5-7% 🌍 NASDAQ:VRTX flexes—value or stretch? (5/9) – RISKS ON TAP • Payers: Journavx needs coverage—hiccups? ⚠️ • Trikafta: 93% of sales—big lean 🏛️ • Comp: Pain rivals, CF safe—for now 📉 Hot streak—can it dodge the bumps? (6/9) – SWOT: STRENGTHS • CF King: Trikafta, Alyftrek lock it in 🌟 • Pain Play: Journavx eyes $ 4B peak 🔍 • Cash: $11.2B—war chest ready 🚦 NASDAQ:VRTX ’s got muscle and moolah! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Trikafta reliance—eggs in one basket 💸 • Opportunities: Casgevy rolls, pain grows 🌍 Can NASDAQ:VRTX zap past the risks? (8/9) – NASDAQ:VRTX ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—Pain pays off big. 2️⃣ Neutral—Solid, but risks linger. 3️⃣ Bearish—Growth hits a wall. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:VRTX ’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?
NASDAQ:VRTXLong
by DCAChampion
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associated with traditional analgesics. The significance of this development cannot be overstated, as it promises a new era where acute pain can be treated effectively and safely, potentially altering the landscape of medical treatment for millions. Journavx operates by selectively inhibiting NaV1.8, a sodium channel vital for pain signaling, thus preventing pain signals from reaching the brain. This mechanism not only offers relief but does so without the side effects that have long plagued opioid use. The implications for healthcare are profound, offering doctors and patients alike a tool that can redefine how we approach pain management in clinical settings. Vertex's success with Journavx showcases the company's commitment to pioneering treatments that address some of the most pressing needs in modern medicine. Financially, this approval has bolstered Vertex's market position, evidenced by a significant uptick in stock performance following the announcement. With a revenue projection for 2025 set between $11.75 and $12.0 billion, Vertex is not just riding the wave of this single approval but is also expanding its therapeutic horizons. The strategic leadership transitions announced alongside this approval signal a robust plan for future innovation, challenging investors and healthcare professionals to think about the evolving landscape of drug development and patient care.  This moment invites us to ponder the future of pharmaceuticals - one where efficacy does not compromise safety, where innovation in treatment could lead to broader societal benefits by reducing dependency on addictive substances. Vertex's journey with Journavx might just be the beginning of a new chapter in medical science, urging us to envision a world where pain management is humane and humane-centered.
NASDAQ:VRTXLong
by UDIS_View
Vertex Pharmaceuticals pioneers with non-opioid painkiller VX-54Vertex Pharmaceuticals Inc., widely recognised for its cystic fibrosis treatments, is venturing into new therapeutic areas , signalling potential growth in new markets. The company is currently advancing its development of non-opioid analgesics, specifically candidate VX-548, which has demonstrated encouraging outcomes in clinical trials. This new drug represents a significant shift in pain management, offering an alternative to opioid medications. Vertex is preparing to seek FDA approval for VX-548 within the year. If approved, this drug could substantially impact the healthcare industry and is projected to achieve peak annual revenues of 5 billion USD – approximately half of Vertex's current annual revenue. Exploring investment opportunities, here is a technical analysis of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX): On the Daily (D1) timeframe, the stock exhibits a 410.00 USD resistance level and support at 392.00 USD. The stock is currently trending downward. Notably, there have been three consecutive trading sessions with a gap up, suggesting that major players might be accumulating buy positions. If the downtrend persists, the next price target could be around 360.50 USD. For traders, breaking the resistance at 410.00 USD could provide a buying opportunity, with a short-term target set at 421.00 USD. If the resistance is surpassed, holding a long position with a target of up to 436.50 USD might be considered for a medium-term strategy. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NASDAQ:VRTX
by RoboMarkets
Stock of the Month: Vertex (VRTX)Our portfolio is up by more than 15% in the month of November. We are strictly following Mark Minervini's Trading Methodology. Here is a quick summary: Mark Minervini's trading methodology, often encapsulated in his SEPA (Specific Entry Point Analysis) system, is a comprehensive approach to trading that emphasizes the importance of timing, risk management, and stock selection. Here’s a concise summary: Trend Template: Minervini looks for stocks in a strong uptrend, using specific criteria for moving averages and price action to determine the health of the trend. Volatility Contraction Pattern (VCP): He identifies stocks undergoing a VCP, a series of tightening price consolidations which often precede a significant breakout. Risk Management: He sets strict stop-loss orders to limit potential losses, often using a maximum risk threshold per trade to manage overall portfolio risk. Buy Points: Minervini waits for a proper pivot point before entering a trade, ensuring the stock is moving on high volume out of a sound base pattern. Leadership: Preference is given to market leaders, stocks that outperform the market with strong earnings growth, sales, return on equity, and profit margins. Market Direction: He trades in harmony with the overall market direction, increasing exposure during bull markets and preserving capital during bear markets. By focusing on these key principles, Minervini aims to capture significant trends, minimize losses, and compound gains efficiently. Remember, this strategy requires discipline, continuous learning, and the ability to adapt to changing market conditions. Stock of the Month November: Vertex Detailed Technical Analysis Price and Moving Averages : The price of VRTX has recently experienced a bullish breakout. It is trading above all key moving averages (MA), including the 50-day, 100-day, and 200-day MAs, which are aligned in ascending order—a bullish signal known as a 'golden cross'. The 50-day MA is often used as a short-term trend indicator, and its position above the longer-term MAs suggests a strong upward trend. Volume : There's a noticeable increase in volume accompanying the price rise, which is a positive sign as it indicates strong buying interest. Moving Average Convergence Divergence (MACD): The MACD line is above the signal line and above zero, which is bullish. The histogram is showing increasing momentum to the upside. Relative Strength Index (RSI): The RSI is above 70, which typically indicates overbought conditions. However, in strong trends, the RSI can remain overbought for extended periods. IBD Ratings: The IBD (Investor's Business Daily) ratings show a high relative strength rating of 93, suggesting that the stock is outperforming 93% of all other stocks in terms of price performance. Bollinger Bands: The price has moved towards the upper Bollinger Band, which could signal that the stock is overextended in the short term. Support and Resistance: The chart shows previous resistance around the $360 level, which appears to have been decisively breached and may now serve as support. Candlestick Analysis: The recent candlesticks show strong bullish bodies, which confirms the buyers' control. Price Targets: If you're using chart patterns for price targets, the recent breakout suggests a continuation of the uptrend. Potential Risks: The overbought RSI readings could indicate a potential pullback or consolidation in the near term. Additionally, the elevated volume on up days should be monitored to ensure it doesn't start declining, which could signal a weakening trend. Here is a link top our updated portfolio: www.tradingview.com
NASDAQ:VRTX
by JS_TechTrading
Vertex’s Stock Heads for All-Time HighVertex Pharmaceuticals Inc. shares were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine. The stock jumped more than 10% Wednesday morning, on pace for its largest percentage gain in more than three years, and was set to cross the $100 billion market-capitalization threshold for the first time. The company’s experimental pain medicine VX-548 produced statistically significant, clinically meaningfully reductions in pain intensity in people with diabetic peripheral neuropathy, a type of nerve damage that can affect people with diabetes, Vertex said in a release. The pain control seen with the drug appears comparable to the “gold standard” pain medicine pregabalin, which is marketed by Viatris Inc. under the brand name Lyrica, Evercore ISI analyst Liisa Bayko wrote in a report Wednesday. Evercore analysts raised their price target on Vertex shares to $405, from $389 previously. The new data on the pain medicine “looks at least as good as or better than investor expectations,” Jefferies analysts said in a note Wednesday. Vertex is working to quickly advance the treatment to Phase 3 studies in diabetic peripheral neuropathy, Vertex’s chief medical officer, Dr. Carmen Bozic, said in a statement. Phase 3 results from a trial of the drug in acute pain are expected in the first quarter of next year. Vertex shares have gained 37% in the year to date, while the S&P 500 is up 21%. NASDAQ:VRTX is trading above the 50, 100 & 200-day Moving Averages indicating the trend might continue.
NASDAQ:VRTXLong
by DEXWireNews
VRTX Entry, Volume, Target, StopEntry: with price above 354.47 Volume: with volume greater than 2M Target: 391 area Stop: Depending on your risk tolerance; 342.3 gets you 3/1 Reward to Risk Ratio. This swing trade idea is not trade advice and is strictly based on my ideas and technical analysis. No due diligence or fundamental analysis was performed while evaluating this trade idea. Do not take this trade based on my idea, do not follow anyone blindly, do your own analysis and due diligence. I am not a professional trader.
NASDAQ:VRTXLong
by tradepatiently
VRTX Long Chance on ChannelNASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago. For me its a very good chance and low price for VRTX. strong up move with good volume crossing the negative trend crossed EMA200 and MA200 on daily chart and also on weeky chart still above EMA200 and MA200 on monthly chart still in positive trend since 2008 good position in the market good cashflow for the next years, even if products are failing
NASDAQ:VRTXLong
by JulianRichard11
1
LFMD - WAVE C ENDING - BUY SOON OR OPTIONS LONGER TERMAll, LFMD had game changing fundamentals last quarter but still under downtrend resisance #2. This is a 3/4 retracement wave C should be ending RSI tells the story on the daily. I am watching EXTREMELY closely here. I think this is going to pop worst case is a double bottom at 7.7 or near it in which case I will absolutely be all in. Fundamnentally/valuation wise I personallly see LFMD at 14-18$ range and probably will go into 20's again from demand/lower float than most in category. As always watch the entire market first and do not enter too early. Just wait for the stars to align and for the break up to happen. Also remember almost everytime on breaks there is the first wave up but wave 2 is almost always a better and safer entry (depends how fast it moves)
NASDAQ:LFMDLong
by DigitalData